Irving, Texas, USA, November 16, 2026
Caris Life Sciences has presented new research demonstrating the value of Whole Transcriptome Sequencing (WTS) in advancing precision oncology and identifying clinically meaningful genetic alterations across different types of cancer. The research was presented at the Association for Molecular Pathology (AMP) 2026 Annual Meeting, highlighting how comprehensive RNA sequencing can help identify novel and rare gene fusions that may not be detected through conventional molecular testing approaches. The company and its research collaborators presented two scientific posters examining gene-fusion patterns across a large collection of solid tumors and specific gynecological cancers. The findings highlight the growing importance of comprehensive molecular profiling, RNA-based sequencing, and genomic data analysis in understanding cancer biology and supporting the development of targeted treatment strategies.
Whole Transcriptome Sequencing Identifies Novel Cancer-Related Gene Fusions
One of the studies evaluated the ability of whole transcriptome sequencing to identify clinically actionable gene fusions across 698,406 solid tumors. Using comprehensive molecular profiling data collected between 2019 and 2026, researchers investigated known and previously unreported fusion events and examined their potential clinical significance. The analysis identified fusion transcripts in 503,460 tumors, representing 72.1% of the total cases. Among fusion-positive tumors, researchers identified 37,325 tumors containing pathogenic or likely pathogenic fusion alterations, while 34,671 contained fusions with therapeutic or diagnostic significance based on the evidence classifications used in the study. An important finding was that more than 91% of the actionable fusion pairs identified were not previously listed in the reference databases used for the analysis. This finding demonstrates the potential of comprehensive RNA sequencing to expand the identification of molecular alterations beyond established reference datasets. The most frequently identified actionable fusion genes included ALK, FGFR2, and FGFR3, while ERG and RSPO3 were among the most frequently observed diagnostic fusion partners. The researchers also examined clinical outcomes associated with targeted therapies in patients with certain gene fusions. In linked healthcare claims analyses, patients with novel or canonical ALK and FGFR2 fusion partners who received matched tyrosine kinase inhibitors (TKIs) demonstrated comparable survival outcomes. Both groups showed longer survival than patients who received non-TKI treatments in the analyzed data. These findings provide additional evidence supporting the investigation of newly identified fusion partners and their potential relevance to targeted treatment selection. However, the results should be interpreted in the context of the retrospective analysis and should not be considered proof that every newly identified fusion will respond to a particular targeted therapy.
Rare PAK Gene Fusions Identified in Gynecological Cancers
The second study focused on identifying rare PAK-family gene fusions in serous carcinomas involving the ovaries, fallopian tubes, and peritoneum. These cancers represent important areas of ongoing oncology research, where understanding uncommon molecular alterations may help improve disease characterization and guide future therapeutic investigations. Researchers identified PAK1, PAK2, or PAK3 gene fusions in 237 tumors, representing approximately 0.17% of the ovarian, fallopian tube, and primary peritoneal serous carcinoma tumors evaluated. The analysis identified several fusion partners, with DLG1 and GAB2 being among the most frequently observed. Researchers also found that the identified fusions retained the portions of PAK genes responsible for producing kinase proteins. These alterations were observed across both high-grade and borderline or low-grade serous carcinoma cases. The identification of these uncommon molecular alterations provides additional information about the genetic diversity of gynecological cancers. Although the findings do not establish an approved targeted treatment for patients carrying these fusions, they may support further research into the biological significance of PAK-family alterations and potential therapeutic approaches.
Advancing Molecular Profiling and Targeted Cancer Research
Caris Life Sciences continues to develop its precision medicine capabilities by combining whole genome sequencing, whole exome sequencing, whole transcriptome sequencing, artificial intelligence, and advanced computational analysis. These technologies enable researchers to investigate complex molecular characteristics of tumors and identify genetic alterations that may influence disease behavior or treatment strategies. RNA-based sequencing is particularly valuable for gene-fusion analysis because it can identify expressed fusion transcripts and provide information about whether genetic rearrangements produce functional RNA molecules. The findings presented at AMP 2026 reinforce the importance of comprehensive molecular profiling in modern oncology research. By identifying novel and rare gene fusions across large tumor datasets, Caris and its collaborators aim to expand scientific understanding of cancer-associated molecular alterations and generate evidence that may support future precision medicine applications. The research highlights how advanced RNA sequencing can contribute to biomarker discovery, targeted therapy research, and more detailed molecular characterization of cancer, supporting continued progress toward individualized approaches to cancer care.
Source: Caris Life Sciences press release



